Nasus Pharma (NSRX) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NextCure (NXTC) has outperformed Nasus Pharma (NSRX) over the past year, losing 38.6% versus a loss of 68.4%. NextCure is the larger company by market cap ($29.5 million vs $26.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NSRX | NXTC |
|---|---|---|
| Share price | $2.29 | $6.45 |
| Market cap | $26.82M | $29.53M |
| 1-day change | -10.20% | -4.87% |
| YTD return | -74.97% | -54.55% |
| 1-year return | -68.41% | -38.63% |
| 5-year return | — | -91.07% |
| EPS (TTM) | $-1.20 | $-6.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | — |
| Net income (latest FY) | $-5.86M | $-55.84M |
| Operating margin | -0.40% | — |
| Net margin | -0.47% | — |
| 52-week high | $9.50 | $15.74 |
| 52-week low | $1.98 | $1.55 |
| Distance from 52-week high | -75.89% | -59.02% |
| Analyst consensus | buy | none |
| Avg. price target upside | +758.95% | +210.08% |
| Average volume | 16.80K | 79.46K |
| Shares outstanding | 11.71M | 4.58M |
| Employees | 7 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed NSRX by 29.8 percentage points over the past year.
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
NSRX vs NXTC FAQ
Which is bigger, Nasus Pharma or NextCure?
NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $26.82M for Nasus Pharma (NSRX).
Which stock has performed better over the past year, NSRX or NXTC?
NXTC returned -38.63% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.
Are Nasus Pharma and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.